Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis

The Lancet

Volumn 371, Issue 9607, 2008, Pages 117-125

  Downs, J R ^h   Gotto, A ^h   Clearfield, M ^h   Holdaas, H ^h   Gordon, D ^h   Davis, B ^h   Koren, M ^h   Dahlof, B ^h   Poulter, N ^h   Sever, P ^h   Wedel, H ^h   Braunwald, E ^h,h   Cannon, C ^h   Goldbourt, U ^h   Kaplinsky, E ^h   Colhoun, H M ^h   Betteridge, D J ^h   Durrington, P N ^h   Hitman, G A ^h   Fuller, J ^h   Neil, A ^h   Wanner, C ^h   Krane, V ^h   Sacks, F ^h   Moye, L ^h   Pfeffer, M ^h   Hawkins, C M ^h   Barter, P ^h   Keech, A ^h   Marchioli, R ^h   Tognoni, G ^h   Franzosi, Maria Grazia ^h   Maggioni, A ^h   Bloomfield, H ^h   Robins, S ^h   Collins, R ^h   Armitage, J ^h   Parish, S ^h   Peto, R ^h   Sleight, P ^h   Pedersen, T ^h   Serruys, P W ^h   Holman, R ^h   Meade, T ^h   Simes, J ^h   MacMahon, S ^h   Marschner, I ^h   Tonkin, A ^h   Shaw, J ^h   Nakamura, H ^h   Knatterud, G ^h   Furberg, C ^h   Byington, R ^h   MacFarlane, P ^h   Cobbe, S ^h,h   Ford, I ^h   Murphy, M ^h   Blauw, G J ^h   Packard, C ^h   Shepherd, J ^h   Kjekshus, J ^h   Wilhelmsen, L ^h   Baigent, C ^h,h   Baxter, A ^h,h   Landray, M ^h   La Rosa, J ^h   Rossouw, J ^h   Probstfield, J ^h   Flather, M ^h   Newman, C ^h   Tobert, J ^h   Varigos, J ^h   White, H ^h   Yusuf, S ^h   Kearney, P M ^h   Blackwell, L ^h,h   Barnes, E ^h   Buck, G ^h   Emberson, J ^h   Kirby, A ^h   Mellies, M ^a   McGovern, M ^a   Barclay, J ^a   Belder, R ^a   Mitchel, Y ^b   Musliner, T ^b   Ansquer, J C ^c   Llewellyn, M ^d   Bortolini, M ^e   Bryzinski, B ^f   Olsson, G ^f   Pears, J ^f   Bander Silbershatz, H ^g   more..

^a BRISTOL MYERS SQUIBB   (United States)

^b Merck

^c Laboratoires Fournier

^d Bayer

^e Novartis Pharma AG

^f ASTRAZENECA   (United Kingdom)

^g Pfizer

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; SYSTEMATIC REVIEW;

EID: 38049033935     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60104-X     Document Type: Article

References (41)

1. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
2. Garcia M., McNamara P., Gordon T., and Kannell W. Morbidity and mortality in diabetics in the Framingham population: sixteen year follow-up study. Diabetes 23 (1974) 105-111
3. Pyörälä K., Laakso M., and Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab 3 (1987) 464-524
4. Stamler J., Vaccaro O., Neaton J., and Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 16 (1993) 434-444
5. Nikkilä E., and Hormila P. Serum lipids and lipoproteins in insulin-treated diabetes. Demonstration of increased high density lipoprotein concentrations. Diabetes 27 (1978) 1078-1086
6. Taskinen M. Controlling lipid levels in diabetes. Acta Diabetol 39 suppl 2 (2002) S29-S34
7. Jacobs D., Blackburn H., Higgins M., et al. Report of the conference on low blood cholesterol: mortality associations. Circulation 86 (1992) 1046-1060
8. Chen Z., Peto R., Collins R., MacMahon S., Lu J., and Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 303 (1991) 276-282
9. Armitage J., and Collins R. Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials. Heart 84 (2000) 357-360
10. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
11. Cholesterol Treatment Trialists' (CTT) Collaboration. Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration. Am J Cardiol 75 (1995) 1130-1134
12. Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer. Vol 1 Worldwide evidence 1985-1990 (1990), Oxford University Press, Oxford
13. Levey A., Bosch J., Lewis J., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
14. Levey A., Greene T., Kusek J., Beck G., and MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11 (2000) 115A (abstr).
15. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
16. Shepherd J., Cobbe S., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
17. Sacks F., Pfeffer M., Moyé L., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
18. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N Engl J Med 336 (1997) 153-162
19. Downs J., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
20. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339 (1998) 1349-1357
21. GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico). Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico). Ital Heart J 1 (2000) 810-820
22. Serruys P., de Feyter P., Macaya C., et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287 (2002) 3215-3222
23. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
24. Shepherd J., Blauw G., Murphy M., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
25. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288 (2002) 2998-3007
26. Sever P., Dahlof B., Poulter N., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
27. Holdaas H., Fellström B., Jardine A., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361 (2003) 2024-2031
28. Colhoun H., Betteridge D., Durrington P., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
29. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
30. Abramson J., and Wright J. Are lipid-lowering guidelines evidence-based?. Lancet 369 (2007) 168-169
31. De Backer G., Ambrosioni E., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 24 (2003) 1601-1610
32. American Diabetes Association. Standards of Medical Care in Diabetes-2007. Diabetes Care 28 suppl 1 (2007) s4-S41
33. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 91 suppl 5 (2005) v1-v52
34. Statins for the prevention of cardiovascular events (Technology Appraisal 94) (2006), National Institute of Healthcare and Clinical Excellence, London
35. Knopp R., d'Emden M., Smilde J., and Pocock S. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29 (2006) 1478-1485
36. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
37. Koren M., and Hunninghake D. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. J Am Coll Cardiol 44 (2004) 1772-1779
38. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 (2006) 549-559
39. Nakamura H., Arakawa K., Itakura H., et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368 (2006) 1155-1163
40. Athyros V., Papageorgiou A., Mercouris B., et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 18 (2002) 220-228
41. Heart Protection Study Collaborative Group. Lifetime cost-effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20536 people. BMJ 333 (2006) 1145-1148